ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Hochhaus A, le Coutre P, Milojkovic D, Kim DDH, Lim SM, Pavlovsky C, Nguyen T, Nicolini FE, Moiraghi B, Grosicki S, Phu CD, Etienne G, Marco de Lucas F, Ayala Diaz RM, Breccia M, Chuah C, Abi Rached R, Pokhriyal H, Ic A, Schuld P, Pilipovic V, Alisch F, Boquimpani CM

Open source

DOI: 10.1038/s41375-026-02965-8
Published: 2026 Jun
Container: Leukemia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41375-026-02965-8,
  title = {ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.},
  author = {Hochhaus A and le Coutre P and Milojkovic D and Kim DDH and Lim SM and Pavlovsky C and Nguyen T and Nicolini FE and Moiraghi B and Grosicki S and Phu CD and Etienne G and Marco de Lucas F and Ayala Diaz RM and Breccia M and Chuah C and Abi Rached R and Pokhriyal H and Ic A and Schuld P and Pilipovic V and Alisch F and Boquimpani CM},
  year = {2026},
  journal = {Leukemia},
  doi = {10.1038/s41375-026-02965-8},
  url = {https://doi.org/10.1038/s41375-026-02965-8}
}

RIS

TY  - JOUR
TI  - ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.
AU  - Hochhaus A
AU  - le Coutre P
AU  - Milojkovic D
AU  - Kim DDH
AU  - Lim SM
AU  - Pavlovsky C
AU  - Nguyen T
AU  - Nicolini FE
AU  - Moiraghi B
AU  - Grosicki S
AU  - Phu CD
AU  - Etienne G
AU  - Marco de Lucas F
AU  - Ayala Diaz RM
AU  - Breccia M
AU  - Chuah C
AU  - Abi Rached R
AU  - Pokhriyal H
AU  - Ic A
AU  - Schuld P
AU  - Pilipovic V
AU  - Alisch F
AU  - Boquimpani CM
PY  - 2026
JO  - Leukemia
DO  - 10.1038/s41375-026-02965-8
UR  - https://doi.org/10.1038/s41375-026-02965-8
ER  -

APA

A, H., P, L. C., D, M., DDH, K., SM, L., C, P., T, N., FE, N., B, M., S, G., CD, P., G, E., F, M. D. L., RM, A. D., M, B., C, C., R, A. R., H, P., A, I., P, S., V, P., F, A., & CM, B. (2026). ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.. Leukemia. https://doi.org/10.1038/s41375-026-02965-8

Source records

pubmed · retrieved 2026-09-25T13:55:07.282Z